Gritstone Bio Profit Margin

The latest profit margin for GRTS is -7825.47% as of June 2024. That compares with -1586.67% in the prior-year period — down 393.2% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Gritstone Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, GRTS's profit margin moved from -1586.67% to -7825.47% — a 393.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Gritstone Bio's valuation or profitability profile.

Against Healthcare companies, GRTS currently prints -7825.47% for profit margin, while the sector average sits near 13.89%. That is roughly 56426.4% below the sector mean. Large gaps often invite a closer look at Gritstone Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Gritstone Bio converts resources into returns. At -7825.47%, GRTS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1586.67% in the prior-year period — down 393.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GRTS's profit margin (-7825.47%), review year-over-year change from -1586.67%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.